酪氨酸激酶抑制剂AG825对喉癌细胞的影响

发布时间：2018-06-16 04:18

本文选题：酪氨酸激酶抑制剂AG + 喉癌Hep-细胞　；参考：《临床耳鼻咽喉头颈外科杂志》2014年18期

【摘要】：目的:通过体外实验检测酪氨酸酶抑制剂AG825对Hep-2细胞增殖及凋亡的影响,并探讨其作用机制。方法:通过MTT法观察酪氨酸酶抑制剂AG825在不同浓度及时间时对Hep-2细胞的增殖抑制作用;流式细胞仪检测其早期凋亡率;Western blot技术检测细胞内信号传导分子的表达水平的变化。结果:不同浓度的AG825对Hep-2细胞增殖均具有抑制作用,并且随着药物浓度的增大及作用时间的延长,抑制作用逐渐增强。流式细胞学检测显示:AG825促进了Hep-2细胞的早期凋亡,并具有剂量依赖性。Western blot结果显示:AG825作用以后,表皮生长因子下游的信号传导蛋白因子p-Akt和p-MAPK表达水平明显降低,并且随着药物浓度的增大,下游的信号传导因子的表达水平依次下降。结论:酪氨酸激酶抑制剂AG825能有效的抑制Hep-2细胞的生长,并促进细胞的早期凋亡。
[Abstract]:Aim: to investigate the effects of tyrosinase inhibitor AG825 on the proliferation and apoptosis of Hep-2 cells in vitro. Methods: the inhibitory effect of tyrosinase inhibitor AG825 on the proliferation of Hep-2 cells at different concentrations and time was observed by MTT assay, and the expression of signal transduction molecules in Hep-2 cells was detected by flow cytometry and Western blot. Results: AG825 at different concentrations could inhibit the proliferation of Hep-2 cells, and the inhibitory effect was gradually enhanced with the increase of drug concentration and the prolongation of action time. Flow cytometric analysis showed that: AG825 promoted the early apoptosis of Hep-2 cells. The results of Western blot in a dose-dependent manner showed that the expression of signaling protein factor p-Akt and p-MAPK in the downstream of epidermal growth factor (EGF) was significantly decreased after treated with WAG825. And with the increase of drug concentration, the expression level of downstream signal transduction factor decreased in turn. Conclusion: AG825, a tyrosine kinase inhibitor, can effectively inhibit the growth of Hep-2 cells and promote the early apoptosis of Hep-2 cells.
【作者单位】：辽宁医学院附属第一医院耳鼻咽喉科;
【基金】：辽宁省计划项目课题——SOCS1沉默增强DC靶向抗喉癌免疫治疗的研究资助(No:2012225019)
【分类号】：R739.65

【参考文献】